Stratec Se

Stratec Se Net Debt per Share

The Net Debt per Share of Stratec Se (SBS.DE) as of Oct 12, 2026 is 8.13 EUR. In the previous year, Net Debt per Share was 6.73 EUR — a change of 20.81% (higher).

Net Debt per Share

8.13EUR

YoY

20.81%

Last updated:

Net Debt per Share of Stratec Se is 2025 8.13 EUR. Net Debt per Share of Stratec Se was 2024 6.73 EUR. It decreases by 20.81% higher compared to the previous year.

The Stratec Se Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
3.69 EUR
Jan 1, 2019
5.70 EUR
Jan 1, 2020
5.79 EUR
Jan 1, 2021
3.01 EUR
Jan 1, 2022
5.19 EUR
Jan 1, 2023
8.87 EUR
Jan 1, 2024
6.73 EUR
Jan 1, 2025
8.13 EUR
The Stratec Se Net Debt per Share history
YEARNet Debt per ShareYoY
8.13EUR+20.81%
6.73EUR-24.15%
8.87EUR+70.98%
5.19EUR+72.47%
3.01EUR-48.07%
5.79EUR+1.73%
5.70EUR+54.17%
3.69EUR+73.59%
2.13EUR-34.84%
3.27EUR-173.40%
-4.45EUR+40.87%
-3.16EUR—
Access this data via the Eulerpool API

Stratec Se Stock analysis

What does Stratec Se do? The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry. Stratec Se is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stratec Se stock

Net Debt per Share of Stratec Se is 8.13 EUR in 2025.

Net Debt per Share of Stratec Se changed from 6.73 EUR to 8.13 EUR, representing a 20.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Stratec Se since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

Other — Stratec Se

All Key Metrics — Stratec Se